Market Research Logo

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Review, H2 2018

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Review, H2 2018

Summary

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) pipeline Target constitutes close to 31 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Poly [ADP Ribose] Polymerase 1 - Pipeline Review, H2 2018, outlays comprehensive information on the Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Poly [ADP-ribose] polymerase 1 (PARP-1) is an enzyme encoded by the PARP1 gene. It is involved in the base excision repair (BER) pathway, by catalyzing the poly (ADP-ribosylation) of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism.

It positively regulates the transcription of MTUS1 and negatively regulates the transcription of MTUS2/TIP150. It is required for PARP9 and DTX3L recruitment to DNA damage sites. PARP1-dependent PARP9-DTX3L-mediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 5, 9, 4 and 3 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Immunology, Respiratory and Undisclosed which include indications Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Solid Tumor, Metastatic Breast Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Small-Cell Lung Cancer, Cervical Cancer, Glioblastoma Multiforme (GBM), Non-Small Cell Lung Cancer, Gastric Cancer, Malignant Mesothelioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Pancreatic Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Adenocarcinoma Of The Gastroesophageal Junction, Bile Duct Cancer (Cholangiocarcinoma), Diffuse Large B-Cell Lymphoma, Metastatic Pancreatic Cancer, Muscle Invasive Bladder Cancer (MIBC), Prostate Cancer, Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Mantle Cell Lymphoma, Metastatic Transitional (Urothelial) Tract Cancer, Neuroblastoma, Non-Hodgkin Lymphoma, Oropharyngeal Cancer, Pancreatic Ductal Adenocarcinoma, Acute Ischemic Stroke, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Promyelocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Biliary Tumor, Bladder Cancer, Brenner Tumor, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Clear Cell Squamous Cell Carcinoma, Esophageal Cancer, Essential Thrombocythemia, Ewing Sarcoma, Follicular Lymphoma, Germ Cell Tumors, Germinomatous (Seminomatous) Germ Cell Tumors, Glioma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hormone-Sensitive Prostate Cancer, Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Leiomyosarcoma, Lung Cancer, Lung Injury, Lung Transplant Rejection, Marginal Zone B-cell Lymphoma, Melanoma, Metastatic Biliary Tract Cancer, Metastatic Colorectal Cancer, Metastatic Ovarian Cancer, Metastatic Renal Cell Carcinoma, Myelofibrosis, Myeloproliferative Disorders, Natural Killer Cell Lymphomas, Neuroendocrine Tumors, Nongerminomatous (Nonseminomatous) Germ Cell Tumors, Parkinson's Disease, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Peritoneal Tumor, Polycythemia Vera, Rectal Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Sarcomas, Soft Tissue Sarcoma, Squamous Non-Small Cell Lung Cancer, T-Cell Lymphomas, Testicular Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Traumatic Brain Injury, Unspecified, Ureter Cancer, Urethral Cancer and Uveal Melanoma.

Furthermore, this report also reviews key players involved in Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30)
  • The report reviews Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report